Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Preferred Stock Liabilities (2023 - 2024)

Contineum Therapeutics has reported Preferred Stock Liabilities over the past 2 years, most recently at $192.6 million for Q1 2024.

  • Quarterly results put Preferred Stock Liabilities at $192.6 million for Q1 2024, changed N/A from a year ago — trailing twelve months through Mar 2024 was $192.6 million (changed N/A YoY), and the annual figure for FY2023 was $192.6 million, changed.
  • Preferred Stock Liabilities for Q1 2024 was $192.6 million at Contineum Therapeutics, roughly flat from $192.6 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for CTNM hit a ceiling of $192.6 million in Q4 2023 and a floor of $192.6 million in Q4 2023.